Logo

TFX

Teleflex Incorporated

TFX

Teleflex Incorporated • NYSE
$114.42 ▼ -0.75% (-0.87)
Market Cap $5.06 B
52w High $195.24
52w Low $102.58
Dividend Yield 1.36%
P/E -15.96
Volume 251.13K
Outstanding Shares 44.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $913.021M ▲ $481.341M ▲ $-408.892M ▼ -44.785% ▼ $-9.24 ▼ $-323.04M ▼
Q2-2025 $780.889M ▲ $275.774M ▲ $122.58M ▲ 15.697% ▲ $2.77 ▲ $222.666M ▲
Q1-2025 $700.669M ▼ $263.869M ▼ $95.002M ▲ 13.559% ▲ $2.08 ▲ $194.818M ▲
Q4-2024 $795.409M ▲ $550.298M ▲ $-136.656M ▼ -17.181% ▼ $-2.95 ▼ $-36.333M ▼
Q3-2024 $764.375M $280.861M $111.004M 14.522% $2.38 $220.245M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $353.997M ▲ $7.872B ▲ $4.05B ▲ $3.822B ▼
Q2-2025 $253.697M ▼ $7.375B ▲ $3.132B ▲ $4.243B ▲
Q1-2025 $284.122M ▼ $7.163B ▲ $3.068B ▲ $4.095B ▼
Q4-2024 $290.188M ▲ $7.098B ▼ $2.82B ▼ $4.278B ▼
Q3-2024 $243.235M $7.486B $3.005B $4.482B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-408.892M ▼ $107.634M ▲ $-767.502M ▼ $756.34M ▲ $97.388M ▲ $77.688M ▲
Q2-2025 $122.58M ▲ $7.742M ▼ $-30.486M ▼ $-23.668M ▲ $-33.556M ▼ $-26.886M ▼
Q1-2025 $95.002M ▲ $73.094M ▼ $-28.794M ▼ $-59.524M ▲ $-10.172M ▼ $43.083M ▼
Q4-2024 $-136.656M ▼ $202.47M ▼ $-23.088M ▼ $-119.115M ▲ $49.885M ▲ $170.448M ▼
Q3-2024 $111.004M $230.976M $-21.23M $-174.818M $39.198M $209.796M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Anesthesia
Anesthesia
 $100.00M ▲$90.00M ▼$100.00M ▲$100.00M ▲
Interventional
Interventional
 $160.00M ▲$140.00M ▼$170.00M ▲$270.00M ▲
Interventional Urology
Interventional Urology
 $80.00M ▲$70.00M ▼$80.00M ▲$70.00M ▼
Other
Other
 $60.00M ▲$50.00M ▼$60.00M ▲$80.00M ▲
Surgical
Surgical
 $120.00M ▲$110.00M ▼$110.00M ▲$120.00M ▲
Vascular Access
Vascular Access
 $190.00M ▲$180.00M ▼$190.00M ▲$190.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Teleflex’s sales have grown steadily over the past several years, showing that demand for its medical devices is generally healthy. However, profits have been much more volatile. Margins were comfortably strong earlier in the period but have shrunk notably in the most recent year, with net income dropping sharply. This likely reflects higher costs, integration and restructuring expenses, or other one‑time hits rather than a collapse in the core business. The overall picture is of a company that is growing revenue but currently working through a period of earnings pressure and margin normalization.

Balance Sheet

Balance Sheet The balance sheet looks relatively solid and gradually improving. Total assets have stayed broadly stable, while shareholder equity has built up over time, indicating retained value in the business. Debt levels have been coming down, which reduces financial risk and interest burden. Cash on hand is adequate but not excessive, so management appears to be balancing liquidity with debt reduction and investment needs. Overall, leverage is moderate and moving in a healthier direction, giving Teleflex some flexibility to support its strategy and acquisitions.

Cash Flow

Cash Flow Cash generation is a relative bright spot. Operating cash flow has strengthened compared with earlier years, and free cash flow has improved as well, even while the company continues to invest in new equipment and capacity. Capital spending remains disciplined and manageable. The contrast between weaker reported earnings and stronger cash flow suggests that some of the recent profit pressure may be tied to accounting items or temporary factors rather than a deterioration in the underlying ability to generate cash. This cash profile helps support ongoing R&D, integration of acquired businesses, and potential future restructuring, including the planned company separation.

Competitive Edge

Competitive Edge Teleflex operates in specialized areas of healthcare where reliability, clinical outcomes, and physician familiarity matter a great deal. Its well‑known brands in vascular access, urology, airway management, and interventional procedures give it meaningful recognition and loyalty among clinicians. The portfolio is diversified across hospital and procedural settings, which reduces dependence on any single product. At the same time, the company faces intense competition from other large med‑tech firms and lower‑cost manufacturers, especially in more commoditized product lines and OEM work. Strategic acquisitions and a global distribution footprint strengthen its position, but integration risks, pricing pressure, and ongoing innovation from rivals remain important competitive challenges.

Innovation and R&D

Innovation and R&D Innovation is a central part of Teleflex’s strategy. The company owns a large patent portfolio and has built or acquired platforms like UroLift for urology, Arrow EZ‑IO for emergency vascular access, MANTA for vascular closure, and advanced catheters for complex cardiac procedures. It is also beginning to incorporate artificial intelligence into devices and workflows. A sizable pipeline of new products, heavily focused on cardiovascular and related areas, is in development. The recent acquisition of BIOTRONIK’s vascular intervention assets expands its technology base and product breadth, while the planned split into two focused companies is a major strategic move that could reshape how R&D and commercialization are prioritized. Execution on these initiatives—getting new products approved, adopted, and integrated smoothly—will be crucial for sustaining growth.

Summary

Teleflex combines a resilient, growing revenue base with currently compressed profitability and a relatively healthy balance sheet and cash flow profile. Its strengths lie in specialized, clinically important product franchises, strong brands, and a history of adding innovative technologies through both internal development and acquisitions. The company is in the middle of a strategic and financial transition: integrating a large vascular acquisition, preparing to separate into two businesses, and managing near‑term margin pressure. How well management navigates cost control, integration, product launches, and the planned split will largely determine whether the recent earnings softness proves temporary or more persistent. Overall, the story is of a solid med‑tech platform with meaningful competitive assets undergoing a complex but potentially value‑enhancing reshaping.

NEWS

November 14, 2025 · 6:30 AM UTC

Teleflex to Present at the Jefferies Global Healthcare Conference in London

Read more

November 6, 2025 · 6:45 AM UTC

Teleflex Announces Quarterly Dividend

Read more

November 6, 2025 · 6:30 AM UTC

Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook

Read more

October 16, 2025 · 4:30 PM UTC

Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details

Read more

September 11, 2025 · 6:30 AM UTC

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients

Read more